Biological activity of plant extracts and isolated compounds from Alchornea laxiflora: Anti-HIV, antibacterial and cytotoxicity evaluation by Ndinteh, D T et al.
South African Journal of Botany 122 (2018) 498–503
Contents lists available at ScienceDirect
South African Journal of Botany
j ourna l homepage: www.e lsev ie r .com/ locate /sa jbBiological activity of plant extracts and isolated compounds from
Alchornea laxiﬂora: Anti-HIV, antibacterial and cytotoxicity evaluationX. Siwe-Noundou a,b,c,d,⁎, D.T. Ndinteh d,e, D.K. Olivier f, D.Mnkandhla b, M. Isaacs b, F.M.Muganza g, J.T.Mbafor c,
S.F. Van Vuuren f, S. Patnala a, H. Hoppe b, R.W.M. Krause a,⁎
a Department of Chemistry, Rhodes University, PO Box 94, Grahamstown 6140, South Africa
b Department of Biochemistry and Microbiology, Rhodes University, PO Box 94, Grahamstown 6140, South Africa
c Department of Organic Chemistry, Faculty of Science, University of Yaounde 1, PO Box: 812, Yaounde, Cameroon
d Department of Applied Chemistry, University of Johannesburg, PO Box 17011, Doornfontein, Johannesburg 2028, South Africa
e Centre for Nanomaterials Science Research, University of Johannesburg, Auckland Park 2028, South Africa
f Department of Pharmacy and Pharmacology, University of the Witwatersrand, 7 York Rd, Parktown 2193, South Africa
g Department of Chemistry, Sefako Makgatho Health Sciences University, Ga-Rankuwa, 0204 Pretoria, South AfricaAbbreviations:ALL,Alchornea laxiﬂora leaf; ALR,Alchor
laxiﬂora stem; ATCC, American type culture collection; BS
colony forming units; CIN, HIV-1 subtype C integrase
Eagle's Medium; DRC, Democratic Republic of Congo; FBS
and Drug Administration; FITC, Fluorescein isothi
immunodeﬁciency virus/acquired immunodeﬁciency syn
du Cameroun (National Herbarium of Cameroon); IC50,
INT, iodonitrotetrazolium chloride; MIC, minimum inh
methicillin-resistant Staphylococcus aureus; PBS, Phospha
⁎ Corresponding authors at: Department of Chemistry
Grahamstown 6140, South Africa.
E-mail addresses: xavsiw@gmail.com; x.siwenoundou
r.krause@ru.ac.za (R.W.M. Krause).
https://doi.org/10.1016/j.sajb.2018.08.010
0254-6299/© 2018 SAAB. Published by Elsevier B.V. All ria b s t r a c ta r t i c l e i n f oArticle history:
Received 28 March 2018
Received in revised form 16 July 2018
Accepted 16 August 2018
Available online 7 September 2018
Edited by A MoteeteeThis study was designed to assess the cytotoxicity, anti-HIV and antibacterial efﬁcacy of various solvent extracts
of roots, stem and leaves of Alchornea laxiﬂora, as well as ﬁve compounds isolated from its methanolic stem ex-
tract viz.; ellagic acid (1); 3-O-methyl-ellagic acid (2), 3-O-β-D-glucopyranosyl-β-sitosterol (3), 3-O-acetyl-
oleanolic acid (4) and 3-O-acetyl-ursolic acid (5). The tested crude extracts were prepared from several solvent
polarities including: hexane (Hex), chloroform (CHCl3), ethyl acetate (EtOAc), ethanol (EtOH), methanol
(MeOH) and water (H2O). The anti-HIV properties were assessed on HIV-1 subtype C integrase while the cyto-
toxicitywas tested againstHela cells. The antibacterial activitywas studied on a panel of pathogens including gas-
trointestinal, skin, respiratory and urinary-tract infection causing Gram positive bacteria viz.; Bacillus cereus
(ATCC 11778), Enterococcus faecalis (ATCC 29212), Staphylococcus aureus (ATCC 25923) and Staphylococcus
saprophyticus (ATCC 15305)] and Gram-negative bacteria, i.e., Escherichia coli (ATCC 25922), Klebsiella
pneumoniae (ATCC 13883), Moraxella catarrhalis (ATCC 23246). All the tested samples were determined to be
non-toxic due to the low inhibitions observed. Themost potent anti-HIV activitywas observed for themethanolic
extract of A. laxiﬂora root (ALR4)with an IC50 value of 0.21 ng/ml, which wasmore active than chicoric acid used
as reference drug (6.82 nM). Roots, stem and leaves of A. laxiﬂora extracts exhibited antibacterial activities
against most of the Gram-positive bacteria with theminimum inhibitory concentrations (MIC) ranging between
50 and 63 μg/ml. Compounds 1–5 displayed antibacterial activities against S. saprophyticus with MIC values as
low as 4 μg/ml. The results inferred from this study demonstrate the potential of A. laxiﬂora root as a source for
new anti-HIV drugs and scientiﬁcally validate the traditional use of A. laxiﬂora in the treatment of gastrointestinal,
skin, respiratory and urinary tract related infections. These results reafﬁrm the ethnopharmacological signiﬁ-
cance of African traditional medicines.
© 2018 SAAB. Published by Elsevier B.V. All rights reserved.Keywords:
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ghts reserved.1. Introduction
The human immunodeﬁciency virus/acquired immunodeﬁciency
syndrome (HIV/AIDS) was ﬁrst reported in 1981 in the United States
of America (USA) (Zhang et al., 2017). It has since become epidemic
worldwide. More than 78 million people have suffered from HIV infec-
tion and about half of this number have died. HIV/AIDS reportedly re-
mains the leading cause of death in Africa (Global HIV Statistics,
2017). The advances in treatment coupled to multiple campaigns of
awareness to preventHIV/AIDShave signiﬁcantly sloweddown the pro-
gression of the disease. Importantly, the antiretroviral therapy signiﬁ-
cantly impacted the progression of the virus, resulting in the decrease
of HIV-related deaths worldwide (Zhang et al., 2017). Additionally, a
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2014 (Zhang et al., 2017). Due to the emergence of drug-resistance de-
veloped bymany HIV/AIDS patients and the associated side effects such
as a weakened immune system (this exposes the affected individuals to
other microbial, viral and parasitic infections), there is a permanent
need for the discovery of new treatments for HIV infection. Natural
products have been an important source for new drug discovery leads
and have led to the development of drugs approved by the USA Food
and Drug Administration (FDA) for treatment of several diseases
(Newman and Cragg, 2016).
Alchornea laxiﬂora (Benth.) Pax & K. Hoffm. (Euphorbiaceae) is a
shrubwidely spread over large parts of Africa. It occurs from eastern Ni-
geria to Ethiopia and South to the Democratic Republic of Congo (DRC),
throughout East Africa to Zimbabwe, Mozambique, north-eastern parts
of South Africa as well as Swaziland. It can grow as high as 6 m (Dalziel,
1937; Schmelzer, 2007). Alchornea laxiﬂora iswidely used as a folkmed-
icine inmany parts of Africa, as a remedy for numerous diseases ranging
from inﬂammation to heart diseases (Burkill, 1998; Dan et al., 2004;
Kayode and Omotoyinbo, 2008). In Cameroon, uses of Alchornea species
have been described in the traditional pharmacopoeia to treat a range of
microbial infections and parasitic diseases (Adjanohoun et al., 1996;
Jiofack et al., 2009). However, A. laxiﬂora leaves in particular, have
been reported to be effective in the treatment of kidney, urinary bladder
inﬂammation and related infectious diseases (Olatunde Farombi et al.,
2003; Sofowora, 2008). Furthermore, in the upper Nyong valley forest
in Cameroon, A. laxiﬂora leaves are used to treat dysentery,
haemorrhoids and urinary-tract infections (Jiofack et al., 2009) and in
Ndop Central sub-division in Cameroon, a decoction (locally known as
Mechango or Bambalang) is taken orally for post-partum pain and in-
ﬂammation (Focho et al., 2009). In Nigeria, A. laxiﬂora is reportedly
used as a topical application to alleviate teething problems in children
(Olatunde Farombi et al., 2003). Phytopharmacological studies gleaned
from various investigations include the anti-inﬂammatory (Ogundipe,
1999), hyposensitive and antihistaminic (Kayode and Omotoyinbo,
2008; Sofowora, 2008) properties of leaf extracts.
2. Materials and methods
2.1. Chemicals
The tested pure compounds include ellagic acid (1); 3-O-methyl-
ellagic acid (2), 3-O-β-D-glucopyranosyl-β-sitosterol (3), 3-O-acetyl-
oleanolic acid (4) and 3-O-acetyl-ursolic acid (5) obtained from the
Phytochemical's Bank of the Medicinal Organic Chemistry and
Nanomaterials Laboratory, Department of Chemistry, Rhodes Univer-
sity, Grahamstown, South Africa. These compounds were recently iso-
lated and identiﬁed from the methanolic extract of Alchornea laxiﬂora
(Euphorbiaceae) stem bark by our research team (Sandjo et al., 2011).
Chicoric acid N 98%, Emetine N 98% and Ciproﬂoxacin hydrochloride N
98% were purchased from Sigma–Aldrich.
2.2. Plant materials
The plant material was collected in bulk from uncultivated farmland
on the Elounden Mount in Yaoundé, Cameroon, in January 2010. The
species was authenticated by Mr. Victor Nana, a botanist from the Na-
tional Herbarium of Cameroon in Yaoundé, where a voucher specimen
(N° 45363/HNC) was deposited.
2.3. Extraction of plant materials for biological assessment
All the collected plant materials (leaf, root and stem) were dried in-
dividually at ambient temperature and ground into ﬁne powder. Each of
the powdered plantmaterialswas soaked in the solvent (10 g plantma-
terial/ 50 ml solvent) in an air-tight container at ambient temperature
for 72 h. Selected solvents - hexane, chloroform, ethyl acetate,methanol, ethanol and water (in that order) were used for successive
extraction of each sample, respectively.
2.4. HIV-1 integrase strand transfer reaction assay
The HIV-1 subtype C integrase (CIN) strand transfer inhibition assay
was adapted from previously described method (Grobler et al., 2002).
Brieﬂy, 20 nM double-stranded biotinylated donor DNA (5′-5 Biotin
TEG/ACCCTTTTAGTCAGTGTGGAAAATCTCTAGCA-3′ annealed to 5′
ACTGCTAGAGATTTTCCACACTGACTAAAAG-3′) was immobilised in
wells of streptavidin coated 96-well microtiter plates (R&D Systems,
USA). Following incubation at room temperature for 40 min and a strin-
gentwash step, 5 μg/ml puriﬁed recombinantHIV- 1 CIN in buffer 1 (50
mm NaCl, 25 mM Hepes, 25 mMMnCl2, 5 mM β-mercaptoethanol, 50
μg/ml BSA, pH 7.5) was added to individual wells. Test samples and
chicoric acid were added to individual wells to a ﬁnal concentration of
20 μM (pure compounds and chicoric acid) and 50 mg/ml (crude ex-
tracts). Recombinant HIV-1 subtype C IN was assembled onto the pre-
processed donor DNA through incubation for 45min at room tempera-
ture. Strand transfer reaction was initiated through the addition of 10
nM (ﬁnal concentration) double-stranded FITC-labelled target DNA
(5′-TGACCAAGGGCTAATTCACT/36-FAM/−3′ annealed to 5′-
AGTGAATTAGCCCTTGGTCA−/36-FAM/−3′) in integrase buffer 2
(same as buffer 1, except 25 mmMnCl2 replaced with 2.5 mmMgCl2).
After an incubation period of 60 min at 37 °C, the plates were washed
using PBS containing 0.05% Tween 20 and 0.01% BSA, followed by the
addition of peroxidase-conjugated sheep anti-FITC antibody (Thermo
Scientiﬁc, USA) diluted 1:1000 in the same PBS buffer. Finally, the plates
were washed and peroxidase substrate (Sure Blue ReserveTM, KPL,
USA) was added to allow for detection at 620 nm using a Synergy MX
(BioTek®) plate reader. Absorbance values were converted to percent-
age enzyme activity relative to the readings obtained from control
wells (enzyme without inhibitor).
2.5. Cytotoxic activity
This was adopted from our previously described method (Mbosso
Teinkela et al., 2018). Brieﬂy, to assess the overt cytotoxicity, samples
were incubated at 25 μg/ml for extracts and 20 μM for pure compounds
in 96-well plates containing HeLa cells (human cervix adenocarci-
noma), maintained in a culture medium made of Dulbecco's Modiﬁed
Eagle's Medium (DMEM) with 5 mM L-glutamine (Lonza) and supple-
mented with 10% fetal bovine serum (FBS) and antibiotics (penicillin/
streptomycin/fungizone - PSF) for 24 h. The number of cells surviving
drug exposure were counted using the resazurin based reagent and
resoruﬁn ﬂuorescence was quantiﬁed (Excitation560/Emission590) in
a multiwell plate reader.
2.6. Single concentration screening
The percentage of cell viability was calculated at a ﬁxed concentra-
tion of 20 μM for pure isolated compounds or 25 μg/ml for natural
plant extracts. Experiments were performed in triplicate wells, and
the standard deviation (SD) was derived. For comparative purposes,
Emetine (which induced cell apoptosis) was used as a positive control
drug standard at a concentration of 10 μM. Samples were tested for
HIV-1 integrase at a concentration of 20 μM in the case of pure com-
pounds and 25 μg/ml for crude extracts and Chicoric acid was used as
positive control for HIV-1 integrase at a concentration of 20 μM.
2.7. Dose response
The IC50 (50% inhibitory concentration) values of tested extract/
compound exhibiting a low percentage viability or low integrase activ-
ity were determined from the resulting dose–response curve by non-
linear regression using Prism 5 program (Version 5.02, Graph Pad
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the low inhibition observed by the preliminary single concentration
screening.
2.8. Antibacterial activity
The antibacterial activity of the crude extracts and pure compounds
was evaluated by the micro-dilution assay (Siwe Noundou et al., 2016)
against four Gram-positive bacteria i.e. B. cereus ATCC 11778, E. faecalis
ATCC 29212, S. aureus ATCC 25923 and S. saprophyticus ATCC 15305,
as well as four Gram-negative bacterial strains i.e. E. coli ATCC 25922,
K. pneumoniae ATCC 13883, M. catarrhalis ATCC 23246 and P. mirabilis
ATCC 43071. All bacterial strains were conﬁrmed pure from stock cul-
tures and maintained in the Pharmaceutical Microbiology Laboratories
at the University of Witwatersrand, Johannesburg, South Africa. The
stock solutions of samples (32 mg/ml for crude extracts and 1 mg/ml
for isolated compounds) were prepared as follows: Acetone was used
for the extracts i.e. Hex, CHCl3 and EtOAc and compounds 4 and 5
while a solution of DMSO/H2O (5:95, v/v) was used for EtOH and
MeOH extracts and compounds 1, 2 and 3. The aqueous extracts were
used as are. All the above stock solutions were placed in duplicate
(using adjacent wells) and further serially diluted (2-fold dilution)
with sterile water in a 96-well microtitre plate to obtain a 1 mg/ml
and 0.031 mg/ml solution in the ﬁnal row for the extracts and isolated
compounds respectively. To the above dilutions in the well plates,
equal volumes (100 μl) of bacterial suspension yielding approximately
an inoculum size of 1 × 106 colony forming units (CFU/ml) were
added. The plates were sealed with sterile seals and incubated at 37 °C
for 24 h. Thereafter, 0.04% (w/v) p-iodonitrotetrazolium (INT) was
added to each well and the plates were kept at ambient temperature
for 6 h. The results were recorded visually under a light source. All
well plate experiments were carried out in triplicate (2 × 3). Sterile
broth containing bacterial suspension was used to monitor the viability
of the test organism, while ciproﬂoxacin hydrochloride (0.01 μg/ml)
was used as the positive antibacterial control. Acetone or DMSO were
used as negative control. The ﬁnal concentration of acetone or DMSO
in the well had no effect on the bacterial growth.
3. Results and discussion
3.1. HIV-1 Integrase inhibitory activity
Most of the root extracts of A. laxiﬂora (ALR series) inhibited the ac-
tivities of HIV-1 Integrase (Fig. 1a and Table 1). The methanolic root ex-
tract (ALR4) exhibited noteworthy HIV-1 Integrase inhibitory activity
with an IC50 value of 0.21 ng/ml, chicoric acid was taken as a reference
(IC50 = 6.82 μM). The ethanolic root extract (ALR5) also displayed
marked HIV-1 Integrase inhibitory activity with an IC50 value of 67.07
μg/ml, while the ethyl acetate root fraction (ALR3) IC50 value was
found to be 6.034 μg/ml. The cytotoxicity studies results (Table 1)
showed that none of these extracts were cytotoxic. The results of oura
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Fig. 1. Dose–response curve of anti-HIV integrase assay for (a): A. laxiﬂora root exﬁndings are in agreementwith previous reports on the anti-HIV efﬁcacy
on A. laxiﬂora. In fact, Buhner, (2012), reported that A. laxiﬂora was
found to be strongly active against HIV-1 and HIV-2 in vitro, more so
than Azidothymidine (AZT) (no IC50 value shown nor the part of the
plant used). AZT is the ﬁrst drug approved by the US FDA in the ﬁght
against AIDS (Zhang et al., 2017). A closely related species of the same
genus namely Alchornea cordifolia was also found to be active against
HIV-1 and HIV-2 (Ayisi and Nyadedzor, 2003).
Themethanolic extract of the stemofA. laxiﬂora (ALS4) inhibited the
activities ofHIV-1 Integrase by 91.75% (Table 1), but the IC50wasnot de-
termined. The activity of isolated compounds fromALS4 (Fig. 2) on HIV-
1 Integrase was also investigated (Fig. 1b and Table1).While all the iso-
lated compounds were found to be non-cytotoxic (Table 1), some of
these compounds inhibited the activities of HIV-1 Integrase (Table 1).
Ellagic acid (1) displayed the best anti-HIV-1 Integrase activity with
IC50 value of 90.23 μM. The IC50 values of 3-O-methylellagic acid (2)
and 3-O-acethyl of oleanolic acid (4) were N 100 μM. This result follows
the same trend as observed in the literature. To this instance, ellagic acid
isolated from Lagerstroemia speciosa L. was found to be non-toxic and to
inhibit HIV-1 activitywith an IC50 value of 73 μg/ml (Nutan et al., 2013).
This result is the ﬁrst report on the identiﬁcation of compounds that can
be responsible for the anti-HIV activity of A. laxiﬂora. It is therefore sug-
gested that ellagic acid can be a potential agent for the development of
novel drugs against HIV-1.
3.2. Antibacterial activity of solvent extracts
The extracts of three plant parts (leaves, stems and roots) of A.
laxiﬂora prepared in the order of solvent polarity (i.e. hexane (Hex),
chloroform (CHCl3), ethyl acetate (EtOAc), Ethanol (EtOH), methanol
(MeOH) and water (H2O) are depicted in Table 2.
The antibacterial observations include inhibitory effects on many of
the selected pathogens representing gastrointestinal, skin, respiratory
and urinary tract infections. Methanol extracts of all three plant parts
were found to be the most active when compared to other extracts.
The best results for the leaf extracts were observed for the EtOAc,
MeOH and EtOH extracts against Klebsiella pneumoniae (MIC 63 μg/ml,
for each of the three extracts), a Gram-negative strain associated with
respiratory ailments (Peleg and Hooper, 2010). Staphylococcus
saprophyticus, a Gram-positive urinary tract pathogen (Hovelius and
Mardh, 1984), was particularly susceptible to most extracts (MIC rang-
ing between 63 and 250 μg/ml) and this is in agreementwith one of the
most commonly listed traditional uses for Alchornea laxiﬂora, in the
treatment of diarrhoea. However, the activity of all extracts on Proteus
mirabilis appeared to be weak compared to S. saphrophyticus. It would
be prudent to consider a study on other urinary tract pathogens which
could provide further information on the wider use of A. laxiﬂora
extracts. The root extracts showed higher activity against B. cereus and
E. faecalis atMICs of 63 μg/ml and on S. aureus at 50 μg/ml. The stem ex-
tracts of ethanol and methanol showed signiﬁcant MIC values on S.
saprophyticus at 63 μg/ml. However, the EtOAc, CHCl3 and Hex extractsb
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tracts and (b): A. laxiﬂora stem bark MeOH extract and isolated compounds.
Table 1
Bioassay data showing percentage activity, IC50 values for inhibition of HIV-1 C integrase activity and PV values for toxicity against HeLa cells.
Sample HIV-1 integrase activitya Cytotoxicity activityb,c
Name Code PA (%) IC50 PV (%) IC50
Crude extracts
A. laxiﬂora root (hexane) ALR1 7.06 nd 121.87±3.60 nd
A. laxiﬂora root (chloroform) ALR2 28.47 nd 107.27±10.29 nd
A. laxiﬂora root (ethylacetate) ALR3 −2.03 6.034 101.69±7.30 nd
A. laxiﬂora root (methanol) ALR4 −1.91 0.0002083 113.45±13.93 nd
A. laxiﬂora root (ethanol) ALR5 −2.39 0.06707 99.57±10.87 nd
A. laxiﬂora root (water) ALR6 −2.99 N500 115.32±9.29 nd
A. laxiﬂora stem (methanol) ALS4 91.39 nd 138.58±2.44 nd
Pure isolated compounds from ALS4
Ellagic acid (1) HPD1 12.80 90.23 109.64±3.49 nd
3-O-methylellagic acid (2) HPD2 1.08 N100 110.64±6.53 nd
3-O-β-D-glucopyranoside of β-sitosterol (3) HPD4 34,41 nd 112.84±8.39 nd
3-O-acethyl of oleanolic acid (4) HPD5 16.39 N100 124.00±1.14 nd
3-O-acethyl of ursolic acid (5) HPD6 91.75 nd 100.85±3.45 nd
References
Chicoric acid −0.48 0.00682
Emetine 0.044
PA: percentage activity; PV: percentage viability; nd: not determined;
PV values are from triplicate experiments 20 μM (compounds) or 25 μg/ml (extracts);
IC50: 50% inhibitory concentration, i.e. the concentration of sample that inhibits/reduces by 50% the activity/growth or proliferation of enzyme integrase/HeLa cells in μg/ml for extracts
and in μM for pure compounds and reference drugs.
a HIV-1 integrase inhibitory activity;
b HeLa (human cervix adenocarcinoma) cells;
c IC50 values of samples were not determined due to the low inhibition observed by the preliminary single concentration screening for cytotoxicity.
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MICs of above 100 μg/ml for activity on B. cereus and E. faecalis and sig-
niﬁcant in the case of the respiratory pathogen K. pneumoniae and the
urinary pathogen S. saprophyticus.
According to Bueno, (2012), plant extracts displaying MIC values
belowor equal to 100 μg/ml are considered to shownoteworthy antimi-
crobial activity (Bueno, 2012). Based on the above statement, we could
consider the A. laxiﬂora plant extract concentrations showing signiﬁcant
MICs below 100 μg/ml as having signiﬁcant antimicrobial activity. This3-O-acetyl-oleanolic acid (4)
O
O
O
OH
O
O
OH
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HO
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O
O
O
O
OH
OH
HO
O
O
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Ellagic acid (1) 3-O-methylellagic acid (2)
Fig. 2. Chemical structureis the ﬁrst report on the comparative antibacterial study of A. laxiﬂora
different parts.3.3. Antibacterial activity of isolated compounds
The ﬁve isolated compounds (Fig. 2) were screened for antibacterial
activity against the same eight pathogens as the extracts (Table 2).3-O-acetyl-ursolic acid (5)
O
O
O
OH
OO
OH
HO
HO
HO
3-O-b-D-glucopyranosyl-b-sitosterol (3)
of compounds 1–5.
Table 2
The MIC values (in μg/ml) exhibited against selected pathogens by the crude extracts of A. laxiﬂora, as well as the pure compounds isolated from the stem bark. Highest activities are in-
dicated in bold.
Samples Gastro-intestinal pathogens Skin pathogen Respiratory pathogens Urinary pathogens
Solvent Code B. cereusa ATCC
11778
E. faecalisa ATCC
29212
E. colib ATCC
25922
S. aureusa ATCC
25923
K. pneumoniaeb
ATCC 13883
M. catarrhalisb
ATCC 23246
P. mirabilisb ATCC
43071
S. saprophyticusa
ATCC 15305
A. laxiﬂora roots
Hex ALR1 500 63 1000 63 2000 2000 1000 125
CHCl3 ALR2 63 50 500 50 125 500 500 63
EtOAc ALR3 250 2000 500 50 125 1000 250 63
MeOH ALR4 63 63 500 50 125 1000 250 63
EtOH ALR5 63 63 500 50 125 500 250 63
H2O ALR6 8000 8000 8000 8000 8000 N8000 N8000 N8000
A. laxiﬂora stem
Hex ALS1 8000 8000 8000 1000 2000 N8000 N8000 250
CHCl3 ALS2 250 2000 500 500 500 2000 2000 250
EtOAc ALS3 250 500 250 500 500 2000 8000 250
MeOH ALS4 1000 1000 500 500 500 500 4000 63
EtOH ALS5 500 1000 250 500 500 500 4000 63
H2O ALS6 8000 8000 8000 8000 4000 N8000 N8000 N8000
A. laxiﬂora leaves
Hex ALL1 500 500 500 250 1000 1000 N8000 250
CHCl3 ALL2 125 125 125 250 500 1000 8000 63
EtOAc ALL3 125 125 125 250 63 125 8000 63
MeOH ALL4 125 250 125 250 63 2000 8000 63
EtOH ALL5 125 250 125 400 63 1000 2000 250
H2O ALL6 4000 1000 4000 1000 8000 N8000 N8000 N8000
Compounds isolated from A. laxiﬂora stem
Compound 1 125 63 63 125 16 125 125 31
Compound 2 125 63 63 125 31 250 250 16
Compound 3 125 63 63 125 31 125 250 4
Compound 4 125 125 63 125 16 16 63 4
Compound 5 125 125 63 125 31 16 63 4
Ciproﬂoxacin
HCl (+
control)
0.313 0.625 0.156 0.312 0.625 0.625 0.078 0.313
Culture* N8000 N8000 N8000 N8000 N8000 N8000 N8000 N8000
Acetone (−
control)*
N8000 N8000 N8000 N8000 N8000 N8000 N8000 N8000
5%
DMSO/Water
(−control)*
N8000 N8000 N8000 N8000 N8000 N8000 N8000 N8000
a Gram positive;
b Gram negative; + positive;− negative.
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All the compounds showed an MIC of 125 μg/ml against B. cereus;
compounds 1, 2 and 3 exhibited an MIC of 63 μg/ml against E. faecalis,
whereas, MICs of 125 μg/ml were observed for compounds 4 and 5
against E. faecalis. The minimum inhibitory concentration against E.
coli was observed at 63 μg/ml for all compounds.
3.3.2. Skin pathogen
All the ﬁve compounds displayed an MIC of 125 μg/ml against S.
aureus.
3.3.3. Respiratory pathogens
All the ﬁve compounds exhibited an MIC of b31 μg/ml against
Gram-negative K. pneumoniae, compounds 4 and 5 displayed antibac-
terial activity with MIC value of 16 μg/ml against M. catarrhalis; com-
pounds 1 and 3 exhibited an MIC of 125 μg/ml against M. catarrhalis
while compound 2 showed an MIC of 250 μg/ml against the same
pathogen.
3.3.4. Urinary pathogens
Compounds 3–5were the most active with an MIC value of 4 μg/ml
against Gram-positive S. saprophyticus. Compounds 4 and 5 were the
most active against P. mirabilis whith MIC value of 63 μg/ml each.Ellagic Acid (1) was evaluated against three strains of Bacillus; i.e. B.
subtilis, B. cereus and B. polymyxa and the results showed antibacterial
activity of ellagic acid (1), with MICs b10 μg/ml for the three species
(Cetin-Karaca, 2011). In the same study, ellagic acid (1) was also evalu-
ated against E. coli and displayed an antibacterial activitywithMIC value
of 20 μg/ml. Previous antibacterial investigation on 3-O-β-D-
glucopyranosyl-β-sitosterol (3) was reported by Seukep et al. (2016)
against P. aeruginosa, K. pneumoniae and E. coli strains and all the MICs
ranged from 32 to 256 μg/ml. 3-O-acetyl-oleanolic acid (4) was studied
against several bacterial strains including S. aureus, B. cereus, two strains
of E. coli, P. aeruginosa and K. pneumoniae by Do Nascimento et al.
(2014). 3-O-acetyl-oleanolic (4) acid exhibited signiﬁcant activity
(MIC ≤1024 μg/ml) against all tested strains except for S. aureus. The
best results were found against E. coli with an MIC value of 32 μg/ml,
and against K. pneumoniae and S. aureus with MIC values of 64 μg/ml
and 128 μg/ml, respectively. In another antibacterial study by Cunha et
al. (2010), the antibacterial activity of 3-O-acetyl-oleanolic acid (4)
against B. cereus, K. pneumoniae, and Streptococcus pneumoniae was
evaluated. The reported MICs were greater than 1000 μg/ml, except
for S. pneumoniae (50 μg/ml). 3-O-acetyl-ursolic acid (5) was tested
against B. cereus, S. aureus, S. epidermidis,methicillin-resistant S. aureus
(MRSA), E. coli and Pseudomonas aeruginosa by Sanpa et al. (2015) and
3-O-acetyl-ursolic acid (5) exhibited an MIC value of 25 μg/ml against
all the tested bacteria.
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In continuation of the quest for discovery of effective anti-HIV and
antimicrobial compounds, screening of herbal extracts and compounds
is indeed an expedient procedure to discover new entities that may be
used in developing future drugs. In this study, the isolated compounds
did not display signiﬁcant anti-HIV integrase activity. The most potent
anti-HIV activity was observed for the methanolic extract of Alchornea
laxiﬂora root (ALR4) with an IC50 of 0.21 ng/ml. This is an indication
that further investigations are required to isolate and identify putative
new anti-HIV integrase from the roots of A. laxiﬂora. Our next objective
is therefore to isolate and identify the anti-HIV integrase compounds
from the roots of A. laxiﬂora. The ﬁve isolated compounds exhibited sig-
niﬁcant activity with MIC values ranging between 4 and 63 μg/ml
against all the bacteria except B. cereus. 3-O-β-D-glucopyranosyl-β-si-
tosterol, 3-O-acetyl-oleanolic acid and 3-O-acetyl-ursolic acid displayed
the highest antibacterial activity (MIC value of 4 μg/ml) against S.
saprophyticus. The roots seem to be the most active plant component
of A. laxiﬂora as the root extracts (MIC as low as 50 μg/ml) were more
active as compared to the stem and leaves extracts. The highest antibac-
terial activities were observed for the medium polarity extracts (EtOH,
MeOH, EtOAc and CHCl3). The antibacterial activity of A. laxiﬂora against
gastro-intestinal (B. cereus, E. faecalis and E. coli), skin (S. aureus), respi-
ratory (K. pneumoniae andM. catarrhalis) and urinary (P. mirabilis and S.
saprophyticus) pathogens is indeed scientiﬁcally demonstrated. The iso-
lated phytosteroid (3-O-β-D-glucopyranosyl-β-sitosterol) and
triterpenoids (3-O-acetyl-oleanolic acid and 3-O-acetyl-ursolic acid)
showed more potent antibacterial activity than the phenolic com-
pounds (ellagic acid and its methyl derivative). These isolated com-
pounds are reported here for the ﬁrst time to be responsible for
antibacterial activities of A. laxiﬂora. It is important to note that the
roots seem to be the most anti-HIV and antibacterial active component
of A. laxiﬂora. The overall results provide evidence that A. laxiﬂora as
well as some of its isolated components (3-O-β-D-glucopyranosyl-β-si-
tosterol, 3-O-acetyl-oleanolic acid and 3-O-acetyl-ursolic acid)might be
potential sources of new anti-HIV and antimicrobial drugs.
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